Oral Immunotherapy in Peanut-Allergic Adults Using Real-World Materials.

In the multi‐centre PALISADE phase III trial of AR101 in 551 peanut allergic individuals, highly significant results were seen in participants aged 17 and under, with 67.2% of the active arm tolerating 600 mg of peanut protein when challenged post treatment versus only 4% of the placebo group [ 9 ].

also in 132,142 other papers

Results did not reach statistical significance for the 10% of participants aged 18–55 years, and AR101 has not been approved for adult treatment.

also in 111,027 other papers